The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Key multiple myeloma breakthroughs at ASH 2025
In this interview, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, provides insight into some of the key multiple myeloma (MM) breakthroughs at the ASH 2025 meeting, highlighting the promising early results with in vivo CAR T-cells and mentioning the Phase III MajesTEC-3 trial (NCT05083169), which may lead to the use of anti-BCMA bispecific antibodies in earlier lines of therapy. Prof. Mohty also touches on the importance of measurable residual disease (MRD) assessment, combination therapies, quality-of-life studies, and novel innovations. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
